ATE480236T1 - Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans - Google Patents
Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliteransInfo
- Publication number
- ATE480236T1 ATE480236T1 AT02720584T AT02720584T ATE480236T1 AT E480236 T1 ATE480236 T1 AT E480236T1 AT 02720584 T AT02720584 T AT 02720584T AT 02720584 T AT02720584 T AT 02720584T AT E480236 T1 ATE480236 T1 AT E480236T1
- Authority
- AT
- Austria
- Prior art keywords
- mrna expression
- pioglitazone
- treatment
- promoting agent
- expression promoter
- Prior art date
Links
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 title 2
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 title 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 title 1
- 229960005095 pioglitazone Drugs 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 108020004999 messenger RNA Proteins 0.000 abstract 4
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 101150092476 ABCA1 gene Proteins 0.000 abstract 1
- 108091028119 ACAT1 mRNA Proteins 0.000 abstract 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 abstract 1
- 102100022594 ATP-binding cassette sub-family G member 1 Human genes 0.000 abstract 1
- 108010090314 Member 1 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 abstract 1
- 102100033616 Phospholipid-transporting ATPase ABCA1 Human genes 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- -1 cholesteryl ester Chemical class 0.000 abstract 1
- 102000004311 liver X receptors Human genes 0.000 abstract 1
- 108090000865 liver X receptors Proteins 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001128222 | 2001-04-25 | ||
| PCT/JP2002/004072 WO2002087580A1 (en) | 2001-04-25 | 2002-04-24 | Abc expression promoters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE480236T1 true ATE480236T1 (de) | 2010-09-15 |
Family
ID=18976958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02720584T ATE480236T1 (de) | 2001-04-25 | 2002-04-24 | Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040077689A1 (de) |
| EP (1) | EP1382336B1 (de) |
| AT (1) | ATE480236T1 (de) |
| CA (1) | CA2445322C (de) |
| DE (1) | DE60237594D1 (de) |
| WO (1) | WO2002087580A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6414002B1 (en) * | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| WO2003020315A1 (fr) * | 2001-08-28 | 2003-03-13 | Sankyo Company, Limited | Compositions medicinales contenant un antagoniste du recepteur d'angiotensine ii |
| CA2572872C (en) * | 2004-07-02 | 2013-10-22 | Sankyo Company Limited | Tissue factor production inhibitor |
| MX2007005129A (es) | 2004-10-27 | 2007-09-11 | Daiichi Sankyo Co Ltd | Compuesto de benceno que tiene 2 o mas sustituyentes. |
| CA2621164A1 (en) * | 2005-08-26 | 2007-03-01 | Shionogi & Co., Ltd. | Derivative having ppar agonistic activity |
| TW200932223A (en) * | 2007-12-13 | 2009-08-01 | Univ Kyushu Nat Univ Corp | Drug-containing nanoparticles |
| US20160199497A1 (en) * | 2014-09-10 | 2016-07-14 | Purdue Research Foundation | Cholesterol Ester-Depleting Nanomedicine for Non-toxic Cancer Chemotherapy |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US5057494A (en) * | 1988-08-03 | 1991-10-15 | Ethicon, Inc. | Method for preventing tissue damage after an ischemic episode |
| US5356913A (en) * | 1990-02-09 | 1994-10-18 | The Upjohn Company | Use of insulin sensitizing agents to treat hypertension |
| IL118778A (en) * | 1995-07-03 | 1999-07-14 | Sankyo Co | Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor |
| WO1997010224A1 (en) | 1995-09-13 | 1997-03-20 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| DK0916651T3 (da) * | 1996-04-04 | 2003-12-01 | Sankyo Co | Phenylalkylcarboxylsyrederivater |
| WO1998005331A2 (en) * | 1996-08-02 | 1998-02-12 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
| JPH1072371A (ja) * | 1996-08-28 | 1998-03-17 | Sankyo Co Ltd | 回腸型胆汁酸トランスポーター阻害剤 |
| ES2320181T3 (es) * | 1997-07-24 | 2009-05-19 | Astellas Pharma Inc. | Composiciones farmaceuticas que tienen un efecto reductor del colesterol. |
| US5893865A (en) * | 1997-09-23 | 1999-04-13 | Baxter Research Medical, Inc. | Apparatus and method for improved aortic incision |
| EA200000687A1 (ru) * | 1997-12-19 | 2000-12-25 | Мерк Энд Ко., Инк. | Производные арилтиазолидиндиона |
| EP1077957B1 (de) * | 1998-05-11 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Oxyiminoalkansäure derivate mit hypoglykämischer und hypolipidemischer wirkung |
| WO1999059586A1 (en) * | 1998-05-19 | 1999-11-25 | Regents Of The University Of California | Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis |
| US5968960A (en) * | 1999-01-14 | 1999-10-19 | The Regents Of The University Of California | Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism |
| TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| US6436993B1 (en) * | 1999-07-13 | 2002-08-20 | The Salk Institute For Biological Studies | Use of RAR antagonists as modulators of hormone mediated processes |
| ATE260912T1 (de) * | 1999-09-08 | 2004-03-15 | Glaxo Group Ltd | Oxazol ppar antagonisten |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| PL356487A1 (en) * | 1999-11-10 | 2004-06-28 | Takeda Chemical Industries, Ltd. | 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| AU1303301A (en) * | 1999-11-10 | 2001-06-06 | Takeda Chemical Industries Ltd. | Body weight gain inhibitors |
| EP1229026A4 (de) * | 1999-11-10 | 2003-09-24 | Takeda Chemical Industries Ltd | Alkoxyiminoalkansäure-derivate |
| JP2004500389A (ja) * | 2000-03-09 | 2004-01-08 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｐｐａｒメディエーターの治療での使用 |
-
2002
- 2002-04-24 AT AT02720584T patent/ATE480236T1/de not_active IP Right Cessation
- 2002-04-24 EP EP02720584A patent/EP1382336B1/de not_active Expired - Lifetime
- 2002-04-24 DE DE60237594T patent/DE60237594D1/de not_active Expired - Lifetime
- 2002-04-24 US US10/468,433 patent/US20040077689A1/en not_active Abandoned
- 2002-04-24 CA CA2445322A patent/CA2445322C/en not_active Expired - Fee Related
- 2002-04-24 WO PCT/JP2002/004072 patent/WO2002087580A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1382336B1 (de) | 2010-09-08 |
| US20040077689A1 (en) | 2004-04-22 |
| EP1382336A1 (de) | 2004-01-21 |
| WO2002087580A1 (en) | 2002-11-07 |
| CA2445322C (en) | 2011-06-14 |
| CA2445322A1 (en) | 2002-11-07 |
| DE60237594D1 (de) | 2010-10-21 |
| EP1382336A4 (de) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60211891D1 (de) | Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes | |
| DE60229041D1 (de) | Verfahren zur erhöhung der leptinspiegel unter verwendung von nikotinsäureverbindungen | |
| SE0301886D0 (sv) | New use V | |
| DE60036169D1 (de) | Methoden zur Behandlung der Hautpigmentierung | |
| DE60328517D1 (de) | Neue verwendung von lycopin zur behandlung von erkrankungen im zusammenhang mit androgenwirkung | |
| SE0301888D0 (sv) | New use VII | |
| DE60335997D1 (de) | Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus | |
| DE60114580D1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
| DE60231804D1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| ATE346614T1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
| DE60137307D1 (de) | Substituierte sapogenine und ihre verwendung | |
| DE60012774D1 (de) | Zusammensetzungen mit hydroxyeicosatetraensäure derivate und verfahren zur verwendung zur behandlung des trockenen auges | |
| DE60112807D1 (de) | Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden | |
| DE60013266D1 (de) | Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| ATE254913T1 (de) | Diacerein zur behandlung von psoriasis | |
| ATE480236T1 (de) | Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans | |
| DE602006020775D1 (de) | Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen | |
| ATE469886T1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen | |
| ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| ATE337005T1 (de) | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis | |
| ATE330596T1 (de) | Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen | |
| DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen | |
| SE0301883D0 (sv) | New use II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |